StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

Stock analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Stock Performance

Shares of Senseonics stock opened at $0.31 on Monday. The business’s 50 day moving average price is $0.33 and its 200 day moving average price is $0.38. The company has a market cap of $184.25 million, a price-to-earnings ratio of -2.38 and a beta of 0.77. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics has a one year low of $0.28 and a one year high of $0.75.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SENS. Vanguard Group Inc. grew its holdings in shares of Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares during the period. Geode Capital Management LLC boosted its stake in Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after buying an additional 179,103 shares during the period. Symmetry Partners LLC acquired a new stake in shares of Senseonics during the third quarter valued at about $164,000. Cubist Systematic Strategies LLC raised its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after acquiring an additional 51,000 shares during the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.